US FDA approves Axsome Therapeutics' migraine drug (updated)

Axsome Therapeutics

30/01/2025 21:18

(Adds approval details throughout)
       Jan 30 (Reuters) - The U.S. Food and Drug Administration
has approved Axsome Therapeutics'  AXSM.O  migraine treatment,
the company said on Thursday.
    The oral drug, branded Symbravo, was approved for the acute
treatment of the condition characterized by recurrent attacks of
moderate to severe throbbing and pulsating pain on one side of
the head.
        Symbravo is a combination of two compounds, meloxicam
and rizatriptan, designed to provide rapid and sustained relief
to acute migraine pain, Axsome said.
  
        The company expects the drug to be commercially
available in the U.S. in about four months. 
  

 (Reporting by Mariam Sunny in Bengaluru; Editing by Maju
Samuel)
 ((Mariam.ESunny@thomsonreuters.com;))